Article
Immunology
Keisuke Yamaguchi, Hiroyuki Shimizu, Keita Takahashi, Takamasa Nagatomo, Tomohiro Nishimura, Miyuki Matsumoto, Tetsuo Koshizuka, Hiroaki Mori, Naoki Inoue, Masaharu Torikai
Summary: Congenital cytomegalovirus (CMV) infections are a major cause of hearing loss and neurological disabilities in children, highlighting the importance of developing CMV vaccines. However, the efficacy of the current MF59-adjuvanted glycoprotein B vaccine in protecting against natural infection is limited, and non-neutralizing functions of antibodies may play important roles in pathogenesis and vaccine design.
Article
Virology
Xiangyu Huang, Guihu Yin, Yiqin Cai, Jianing Hu, Jingwen Huang, Qingtao Liu, Xiuli Feng
Summary: In this study, three novel neutralizing epitopes were identified in the HA protein of H9N2 avian influenza virus, which could provide valuable insights for the development of treatment strategies and vaccine design.
Article
Pharmacology & Pharmacy
Jerry Li, Mina Nikanjam, Coleen K. Cunningham, Elizabeth J. McFarland, Emily E. Coates, Katherine V. Houser, Bob C. Lin, Adrian B. McDermott, Britta Flach, Lucio Gama, Richard A. Koup, Barney S. Graham, John R. Mascola, Julie E. Ledgerwood, Edmund V. Capparelli
Summary: This study used population pharmacokinetic modeling to characterize VRC01 PK for dosing selection in pediatric patients. Results showed differences in clearance and subcutaneous bioavailability of VRC01 between infants and adults, with rapid absorption observed in infants with potential therapeutic levels reached quickly.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Food Science & Technology
Carlos Correa-Netto, Marcelo A. Strauch, Marcos Monteiro-Machado, Ricardo Teixeira-Araujo, Juliana Guzzo Fonseca, Moema Leitao-Araujo, Maria Lucia Machado-Alves, Libia Sanz, Juan J. Calvete, Paulo A. Melo, Russolina Benedeta Zingali
Summary: Polyclonal antibodies have been the only scientifically validated treatment for snakebites for over a century, but there have been moderate innovations in this immunotherapy. New strategies and approaches are being explored to develop next-generation antivenoms.
Article
Virology
Liyan Wang, Fan Yang, Yixin Xiao, Bin Chen, Fumin Liu, Linfang Cheng, Hangping Yao, Nanping Wu, Haibo Wu
Summary: This study obtained three monoclonal antibodies against influenza virus from mice immunized with the HA protein of A/Michigan/45/2015(H1N1), demonstrating strong preventive and therapeutic effects. Two amino acid mutations were discovered, and one of the antibodies still showed protective efficacy after 24 hours of infection.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Immunology
Yoshiaki Nishimura, Olivia K. Donau, Joana Dias, Sara Ferrando-Martinez, Eric Jesteadt, Reza Sadjadpour, Rajeev Gautam, Alicia Buckler-White, Romas Geleziunas, Richard A. Koup, Michel C. Nussenzweig, Malcolm A. Martin
Summary: The study found that combination bNAb immunotherapy initiated on day 3 post-infection maintained durable CD8(+) T cell-mediated suppression of SHIVAD8 viremia and CD4(+) T cell levels in most of the treated monkeys during nearly 6 years of observation, with CD8(+) T cell immunity being the principal correlate of virus control. Treatment interventions beginning on week 2 post-infection also conferred controller status to some monkeys, but the time to suppression of plasma viremia was significantly delayed compared to early intervention on day 3.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Biotechnology & Applied Microbiology
K. Yeon Choi, Nadia S. El-Hamdi, Alistair McGregor
Summary: The research suggests that multiple strains of human cytomegalovirus can cause congenital cytomegalovirus. Studies on small animal models have shown that gB vaccines perform well in terms of protection, but there are differences in compatibility with different viral strains. Pentamer complex antibodies have a significant impact on neutralization of non-fibroblast cell infection.
JOURNAL OF GENERAL VIROLOGY
(2021)
Article
Cell Biology
Joshua Tan, Hyeseon Cho, Tossapol Pholcharee, Lais S. Pereira, Safiatou Doumbo, Didier Doumtabe, Barbara J. Flynn, Arne Schon, Sachie Kanatani, Samantha O. Aylor, David Oyen, Rachel Vistein, Lawrence Wang, Marlon Dillon, Jeff Skinner, Mary Peterson, Shanping Li, Azza H. Idris, Alvaro Molina-Cruz, Ming Zhao, Lisa Renee Olano, Patricia J. Lee, Alison Roth, Photini Sinnis, Carolina Barillas-Mury, Kassoum Kayentao, Aissata Ongoiba, Joseph R. Francica, Boubacar Traore, Ian A. Wilson, Robert A. Seder, Peter D. Crompton
Summary: This study demonstrates that circulating IgA plays a role in immunity to malaria, particularly in response to P. falciparum sporozoites. The research also identifies a specific target, the amino terminus of the circumsporozoite protein, for functional antibodies that reduce liver parasite burden.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Virology
Wei Wen, Xinghua Chen, Qiang Lv, Huanchun Chen, Ping Qian, Xiangmin Li
Summary: Researchers have produced five monoclonal antibodies that can detect SVV infection, and these antibodies exhibit high neutralizing titers to SVV. The smallest linear neutralizing epitope (153)QELNEE(158) has been identified. These monoclonal antibodies and identified epitopes are important for further research on VP2 structure and function, as well as the development of diagnostic methods for different SVV strains. Moreover, the epitope recognized by these monoclonal antibodies against VP2 protein may provide insights for the development of novel SVV vaccines and oncolytic viruses.
Article
Biochemistry & Molecular Biology
Huiling Xu, Guangwei Han, Ying Lu, Zehui Liu, Lina Tao, Fang He
Summary: This study produced a batch of neutralizing monoclonal antibodies against CSFV, some of which showed neutralizing reactivity against the virus. Three highly conserved linear neutralizing epitopes were identified, playing a role in virus internalization and attachment, and their prophylactic and therapeutic functions were confirmed in vivo.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Article
Virology
Huan Hu, Rongfei Liu, Qianlin Li, Jin Wang, Qiang Deng, YuYing Lu, Qin Wu, Zeliang Chen, Jiahai Lu
Summary: In this study, ZIKV envelope protein domain III was expressed in E. coli to produce monoclonal antibodies. Ten monoclonal cell lines were identified, with one (mAb 8B6) showing neutralizing activity against ZIKV. Nine other mAbs could also recognize ZIKV, suggesting their potential use for ZIKV diagnosis.
Article
Immunology
Jeffrey R. Dorfman, Sashkia R. Balla, Jayani Pathirana, Michelle J. Groome, Shabir A. Madhi, Penny L. Moore
Summary: In nonprimary maternal CMV infection, higher levels of antibodies targeting specific epitopes on CMV pentamer were found in transmitters compared to nontransmitters, suggesting antibody boosting but not protection against congenital CMV infection. No evidence was found to support a reduced risk of congenital CMV infection with higher levels of CMV-specific antibodies.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Renato Kaylan Alves de Oliveira Franca, Jacyelle Medeiros Silva, Lucas Silva Rodrigues, Dimitri Sokolowskei, Marcelo Macedo Brigido, Andrea Queiroz Maranhao
Summary: This study utilized phage display technology to select human antibodies targeting the fusion loop region of the Zika virus. Three antibodies that can neutralize Zika virus infection were obtained through four rounds of selection. Due to the high conservation of the fusion loop region, these new antibodies have the potential to be used in therapeutic interventions against Zika virus and other flavivirus illnesses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Hang Su, Xiaohua Ye, Daniel C. Freed, Leike Li, Zhiqiang Ku, Wei Xiong, Peng Gao, Xinli Liu, Diana Montgomery, Weifeng Xu, Amy S. Espeseth, Dai Wang, Ningning Ma, Tong-Ming Fu, Ningyan Zhang, Zhiqiang An
Summary: The study developed a bispecific antibody against HCMV by combining the strengths of two different neutralizing antibodies, showing both broad neutralization capacity and high potency. It demonstrated potential clinical therapeutic effects in multiple cell lines and maintained its activity after 21 days in circulation, providing a proof-of-concept for developing bispecific neutralizing antibody therapies against HCMV infection.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Cell Biology
Chen-Yi Chiang, Mei-Yu Chen, Chia-Wei Hsu, Chia-Yeh Liu, Yu-Wen Tsai, Hung-Chun Liao, Jia-Ying Yan, Zih-Shiuan Chuang, Hsin- Wang, Chien-Hsiung Pan, Chia-Yi Yu, Guann-Yi Yu, Ching-Len Liao, Shih-Jen Liu, Hsin-Wei Chen
Summary: This study generated high-quality monoclonal antibodies using a DNA prime-protein boost approach and found that one antibody displayed the best potency in terms of binding affinity and neutralizing capacity. This antibody was able to protect animals from SARS-CoV-2 infection. The results suggest that a combination of multiple monoclonal antibodies may be the best strategy for treating future SARS-CoV-2 variant outbreaks.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
